CSF2 and rheumatoid arthritis: Overall, therapies targeting GM-CSF represent a significant step forward in the development of personalized treatment strategies for RA, yet their successful translation into routine clinical practice will require the systematic resolution of these outstanding issues through rigorously designed long-term studies incorporating biomarker-based stratification and combination therapy frameworks.